FDA Accepts Supplement for CARDIOGEN-82 by BRACCO
The FDA has accepted a supplemental application for CARDIOGEN-82, a radiopharmaceutical used in cardiac imaging.
Asset / Drug
Drug and asset intelligence for BRACCO with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.